ArticleJACC. Advances2026
Optimizing Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Through Integrated Care Strategies.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperkalemia is a critical barrier to mineralocorticoid receptor antagonist (MRA) optimization in heart failure (HF) patients with reduced ejection fraction (HFrEF).
objectivesThe objective of the study was to explore and evaluate a pragmatic, interdisciplinary strategy to safely optimize MRA use in high-risk patients.
methodsWe conducted a prospective, observational study comparing patients at risk of hyperkalemia with HFrEF who were exposed to structured MRA titration, via dietitian-guided potassium restriction, remote monitoring, and potassium binder use, to a propensity-matched cohort followed on Medly, a telemonitoring program. A matched win-ratio was applied to assess the hierarchical composite outcome between the 2 cohorts. Outcomes evaluated were MRA optimization, left ventricular ejection fraction improvement, hyperkalemia events, and HF-related hospitalizations.
resultsAmong 185 patients (51 exposure and 134 Medly), the exposure group had a higher baseline potassium (5.1 vs 4.2 mmol/L, P < 0.001) and a higher use of potassium binders compared to the Medly group (53% vs 7%, P < 0.001). After 1:1 propensity matching (82 pairs), the exposure cohort had significantly higher MRA optimization rates (HR: 4.67; 95% CI: 1.93-11.27; P < 0.001), and fewer HF hospitalizations (P = 0.014). The composite win ratio which included death, HF hospitalization, left ventricular ejection fraction improvement, and hyperkalemic events significantly favored the exposure group (2.5; 95% CI: 1.3-6.35; P = 0.005).
conclusionsA multidisciplinary approach combining dietary counseling, remote monitoring, and potassium binders was associated with improved optimization of MRA therapy in HFrEF patients at risk of hyperkalemia. This model may offer potential clinical benefit and underscores the value of team-based care in HF management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.